Drug intelligence / Profile preview

AR231

Development stage: Preclinical
Lead developer: Anshi Pharmaceutical
Modality: Small Molecules

Overview

AR231 is a small molecule drug candidate currently in preclinical development by Anshi Pharmaceutical for the treatment of osteoporosis. As of the latest pipeline updates, the drug is in the lead optimization stage. The therapeutic goal of the AR231 program is to enhance bone strength and improve bone health in patients with osteoporosis. Detailed information regarding its specific molecular target, mechanism of action, and pharmacokinetics has not yet been released by the developer.

Beyond the preview

Go deeper on AR231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR231.

Explore the full profile